We are live on ! Find out more
CCM

Cutter Capital Management Portfolio holdings

AUM $230M
1-Year Est. Return 11.53%
This Fund
S&P 500
This Quarter Est. Return
+2.37%
1 Year Est. Return
+11.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$230M
AUM Growth
-$14.4M
Cap. Flow
-$13.6M
Cap. Flow %
-5.94%
Top 10 Hldgs %
62.84%
Holding
31
New
10
Increased
5
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$17.2M
2
BIIB icon
Biogen
BIIB
+$16.2M
3
LLY icon
Eli Lilly
LLY
+$15M
4
ROIV icon
Roivant Sciences
ROIV
+$14.1M
5
VRNA
Verona Pharma
VRNA
+$9.57M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$22.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$20.5M
3
ABBV icon
AbbVie
ABBV
+$18.1M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$15.1M
5
RPRX icon
Royalty Pharma
RPRX
+$12.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$18M 7.83%
+295,000
New +$17.2M
AMGN icon
2
Amgen
AMGN
$198B
$15.6M 6.78%
50,000
+11,910
+31% +$3.52M
BIIB icon
3
Biogen
BIIB
$30.4B
$15.5M 6.76%
+113,500
New +$16.2M
LLY icon
4
Eli Lilly
LLY
$1.05T
$14.9M 6.47%
+18,000
New +$15M
INSM icon
5
Insmed
INSM
$23.5B
$14.2M 6.19%
186,384
-24,500
-12% -$1.87M
RARE icon
6
Ultragenyx Pharmaceutical
RARE
$2.88B
$13.7M 5.98%
379,303
-27,500
-7% -$1.14M
BBIO icon
7
BridgeBio Pharma
BBIO
$15.9B
$13.5M 5.88%
390,644
-169,700
-30% -$5.72M
PRGO icon
8
Perrigo
PRGO
$1.48B
$13.4M 5.85%
479,517
+185,000
+63% +$4.8M
ROIV icon
9
Roivant Sciences
ROIV
$24.8B
$13.1M 5.71%
+1,300,000
New +$14.1M
TEVA icon
10
Teva Pharmaceuticals
TEVA
$37.3B
$12.3M 5.37%
801,806
+216,923
+37% +$3.87M
RPRX icon
11
Royalty Pharma
RPRX
$25.8B
$11.1M 4.84%
356,894
-407,965
-53% -$12.9M
TARS icon
12
Tarsus Pharmaceuticals
TARS
$2.61B
$10.5M 4.59%
205,000
+92,500
+82% +$4.57M
VRNA
13
DELISTED
Verona Pharma
VRNA
$10.2M 4.42%
+160,000
New +$9.57M
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.8B
$7.95M 3.46%
+24,000
New +$7.89M
SMMT icon
15
Summit Therapeutics
SMMT
$10.7B
$7.72M 3.36%
+400,000
New +$8.02M
HALO icon
16
Halozyme
HALO
$9.23B
$7.66M 3.33%
+120,000
New +$6.97M
CYTK icon
17
Cytokinetics
CYTK
$10.9B
$7.03M 3.06%
+175,000
New +$8.04M
AGIO icon
18
Agios Pharmaceuticals
AGIO
$2.36B
$6.9M 3%
235,350
-66,273
-22% -$2.2M
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
$6.01M 2.62%
418,127
+271,051
+184% +$4.44M
RCUS icon
20
Arcus Biosciences
RCUS
$3.44B
$5.74M 2.5%
+731,818
New +$8.48M
NAMS icon
21
NewAmsterdam Pharma
NAMS
$3.7B
$4.53M 1.97%
221,152
-116,000
-34% -$2.58M
ABBV icon
22
AbbVie
ABBV
$450B
– –
-101,996
Closed -$18.1M
AKRO
23
DELISTED
Akero Therapeutics
AKRO
– –
-230,000
Closed -$6.4M
JANX icon
24
Janux Therapeutics
JANX
$992M
– –
-120,000
Closed -$6.42M
JNJ icon
25
Johnson & Johnson
JNJ
$609B
– –
-141,572
Closed -$20.5M
1
2

Similar funds

SAM
Selway Asset Management $242M AUM 7.7% 1-Year Est. Return
CW
Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return
IAM
Impact Asset Management Vienna $255M AUM
BCM
BluePointe Capital Management Menlo Park, California $262M AUM 9.24% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
LA
Lane & Associates Moorestown, New Jersey $186M AUM 5.34% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

Cutter Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Cutter Capital Management held 31 positions worth $230M, down 5.9% from $244M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Cutter Capital Management withdrew a net $13.6M in Q1 2025, closing 10 positions and reducing 6 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Cutter Capital Management opened a new position in Bristol-Myers Squibb worth $18M.

  • Cutter Capital Management's largest Q1 2025 buy was Bristol-Myers Squibb: 295,000 shares worth $18M.
  • Cutter Capital Management added most to Perrigo in Q1 2025, an estimated $4.8M increase.
  • Cutter Capital Management's biggest Q1 2025 reduction was Royalty Pharma, cutting an estimated $12.9M.
  • Cutter Capital Management fully exited Regeneron Pharmaceuticals in Q1 2025, selling an estimated $22.4M.
  • Cutter Capital Management's ten largest holdings make up 63% of its $230M portfolio in Q1 2025.
  • Cutter Capital Management opened 10 new positions and closed 10 in Q1 2025.
  • Cutter Capital Management's portfolio value fell 5.9% quarter-over-quarter to $230M.

Based on Cutter Capital Management's 13F filing for Q1 2025, filed 15 May 2025.